We are live on ! Find out more
OA

Oak Associates Portfolio holdings

AUM $1.49B
1-Year Est. Return 34.25%
This Fund
S&P 500
This Quarter Est. Return
+1.15%
1 Year Est. Return
+34.25%
3 Year Est. Return
+111.6%
5 Year Est. Return
+123.41%
10 Year Est. Return
+571.62%
AUM
$822M
AUM Growth
-$9.87M
Cap. Flow
-$15M
Cap. Flow %
-1.82%
Top 10 Hldgs %
37.07%
Holding
185
New
7
Increased
36
Reduced
42
Closed
12

Top Buys

Rank Stock Value
1
WFC icon
Wells Fargo
WFC
+$7.89M
2
EW icon
Edwards Lifesciences
EW
+$1.56M
3
OSPN icon
OneSpan
OSPN
+$1.16M
4
KEYS icon
Keysight
KEYS
+$733K
5
SNY icon
Sanofi
SNY
+$725K

Top Sells

Rank Stock Value
1
MTB icon
M&T Bank
MTB
+$7.95M
2
BCR
CR Bard Inc.
BCR
+$3.09M
3
XOM icon
ExxonMobil
XOM
+$3.04M
4
EPC icon
Edgewell Personal Care
EPC
+$2.4M
5
ZBH icon
Zimmer Biomet
ZBH
+$1.96M

Sector Composition

Rank Sector Weight
1 Technology 35.18%
2 Financials 23.37%
3 Healthcare 16.54%
4 Communication Services 6.83%
5 Consumer Discretionary 3.82%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AVG
76
DELISTED
AVG Technologies N.V.
AVG
$2.5M 0.3%
91,700
– –
GSBC icon
77
Great Southern Bancorp
GSBC
$863M
$2.48M 0.3%
58,900
+180
+0.3% +$7.18K
SIMO icon
78
Silicon Motion
SIMO
$9.19B
$2.42M 0.29%
69,800
+13,500
+24% +$440K
RDS.A
79
DELISTED
Royal Dutch Shell PLC ADS Class A
RDS.A
$2.37M 0.29%
41,523
+894
+2% +$54.4K
SNY icon
80
Sanofi
SNY
$104B
$2.35M 0.29%
47,500
+14,300
+43% +$725K
LLY icon
81
Eli Lilly
LLY
$1.07T
$2.34M 0.28%
28,000
-1,400
-5% -$107K
NVS icon
82
Novartis
NVS
$295B
$2.32M 0.28%
26,338
– –
SYK icon
83
Stryker
SYK
$127B
$2.25M 0.27%
23,600
– –
ACH
84
Accendra Health
ACH
$240M
$2.2M 0.27%
64,600
– –
JNJ icon
85
Johnson & Johnson
JNJ
$635B
$2.12M 0.26%
21,700
– –
BHI
86
DELISTED
Baker Hughes
BHI
$2.06M 0.25%
33,400
-1,150
-3% -$75.2K
FTNT icon
87
Fortinet
FTNT
$112B
$2.04M 0.25%
247,000
+62,000
+34% +$481K
IPG
88
DELISTED
Interpublic Group of Companies
IPG
$2.01M 0.25%
104,530
-9,120
-8% -$189K
OCR
89
DELISTED
OMNICARE INC
OCR
$1.99M 0.24%
21,100
– –
CRL icon
90
Charles River Laboratories
CRL
$10.9B
$1.96M 0.24%
27,900
– –
KEYS icon
91
Keysight
KEYS
$54.5B
$1.93M 0.24%
61,990
+21,440
+53% +$733K
GSK icon
92
GSK
GSK
$103B
$1.9M 0.23%
36,480
+6,240
+21% +$351K
UNH icon
93
UnitedHealth
UNH
$382B
$1.89M 0.23%
15,500
– –
PDCO
94
DELISTED
Patterson Companies, Inc.
PDCO
$1.87M 0.23%
38,400
– –
NXPI icon
95
NXP Semiconductors
NXPI
$68B
$1.79M 0.22%
18,250
+3,400
+23% +$349K
MCK icon
96
McKesson
MCK
$98.5B
$1.7M 0.21%
7,550
– –
EW icon
97
Edwards Lifesciences
EW
$47.6B
$1.64M 0.2%
+69,000
New +$1.56M
ILMN icon
98
Illumina
ILMN
$29.4B
$1.57M 0.19%
7,402
-1,634
-18% -$319K
DGX icon
99
Quest Diagnostics
DGX
$25.1B
$1.54M 0.19%
21,300
– –
AIZ icon
100
Assurant
AIZ
$13.7B
$1.49M 0.18%
22,300
+130
+0.6% +$8.38K
2 3
4
5 6

Similar funds

FAT
First American Trust Santa Ana, California $1.49B AUM 21.98% 1-Year Est. Return
AIA
Ally Invest Advisors Charlotte, North Carolina $1.49B AUM 14.08% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.49B AUM 10.4% 1-Year Est. Return
PIM
Plato Investment Management Sydney, NSW, Australia $1.49B AUM 28.65% 1-Year Est. Return
NAM
Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return
RIM
Rush Island Management New York $1.49B AUM 4.65% 1-Year Est. Return
SB
Simmons Bank Pine Bluff, Arkansas $1.49B AUM 23.32% 1-Year Est. Return
MHS
M Holdings Securities Portland, Oregon $1.48B AUM 26.15% 1-Year Est. Return

Oak Associates's Q2 2015 Portfolio in Review

As of Q2 2015, Oak Associates held 185 positions worth $822M, down 1.2% from $831M the previous quarter. Its ten largest holdings account for 37% of the portfolio.

Oak Associates's Q2 2015 filing shows 7 new, 36 increased, 42 reduced and 12 closed positions. Its largest new stake was Edwards Lifesciences: 69,000 shares worth $1.64M. The largest sale was M&T Bank, an estimated $7.95M.

By sector, the portfolio is most concentrated in Technology at 35% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.

  • Oak Associates's largest Q2 2015 buy was Edwards Lifesciences: 69,000 shares worth $1.64M.
  • Oak Associates added most to Wells Fargo in Q2 2015, an estimated $7.89M increase.
  • Oak Associates's biggest Q2 2015 reduction was CR Bard Inc., cutting an estimated $3.09M.
  • Oak Associates fully exited M&T Bank in Q2 2015, selling an estimated $7.95M.
  • Oak Associates's ten largest holdings make up 37% of its $822M portfolio in Q2 2015.
  • Oak Associates opened 7 new positions and closed 12 in Q2 2015.
  • Oak Associates's portfolio value fell 1.2% quarter-over-quarter to $822M.

Based on Oak Associates's 13F filing for Q2 2015, filed 11 Aug 2015.